乳腺癌患者焦虑与抑郁患病率元分析：合并患病率分别为47.9%和44.3%

SYSTEMATIC REVIEW article

Front. Psychol.

Sec. Psycho-Oncology

Volume 17 - 2026 | doi: 10.3389/fpsyg.2026.1869669

Reviewed by

2A

2 Anonymous reviewers

SYSTEMATIC REVIEW article

Front. Psychol.

Sec. Psycho-Oncology

Abstract

Introduction: Depression and anxiety are frequently reported among women with breast cancer, but prevalence estimates vary substantially across settings and assessment instruments. This meta-analysis synthesized recent international evidence and examined overall, severity-stratified, and instrument-specific prevalence estimates. Methods: We searched PubMed, Web of Science, Embase, the Cochrane Library, APA PsycINFO, and Scopus for observational studies published from January 2015 through September 10, 2026. Proportions were pooled with a random-effects model after Freeman-Tukey double-arcsine transformation. Prespecified subgroup analyses examined region, assessment instrument, and study design; publication-year meta-regression and formal tests for small-study effects were also conducted. A quality-threshold sensitivity analysis re-included all otherwise eligible quality-appraised reports with extractable event counts and denominators. Results: Sixty-nine reports underwent quality appraisal; 52 entered the primary meta-analysis and 17 did not exceed the prespecified quality thresholds. The 52 reports represented 16,850 independent participants. Depression data comprised 49 reports and 16,504 participants, and anxiety data comprised 39 reports and 11,536 participants. The pooled prevalence was 44.3% for depression (95% CI: 38.3%-50.4%; I2 = 98.3%) and 47.9% for anxiety (95% CI: 40.9%-54.9%; I2 = 98.2%). Re-including all quality-appraised reports produced pooled estimates of 44.6% for depression (95% CI: 39.6%-49.6%; 66 reports) and 48.1% for anxiety (95% CI: 41.0%-55.3%; 53 reports), absolute changes of 0.27 and 0.24 percentage points, respectively. Publication year was not a significant moderator for either outcome. Conclusion: Depression and anxiety symptoms were frequently reported, but estimates varied markedly across populations and instruments. The pooled estimates should be interpreted as descriptive summaries rather than precise universal prevalence values. Study-defined severity estimates and instrument-specific results may inform screening, but direct cross-instrument comparisons require caution.

Keywords

Anxiety, breast cancer, Depression, Meta-analysis, Prevalence

Received

05 May 2026

Accepted

28 September 2026

Copyright

© 2026 Jia, Chen, Liu, Bai, Chen, Zhang, Bi, Zhang, Liu and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence:

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.